BioLineRx (BLRX) Total Debt (2011 - 2026)

BioLineRx's Total Debt history runs 12 years deep, the most recent figure standing at $8.9 million for Q4 2025.

• In Q4 2025, Total Debt fell 33.47% year-over-year to $8.9 million; the TTM figure through Dec 2025 stood at $8.9 million (down 33.47% YoY), while the FY2025 annual figure was $8.9 million, down 33.47% from the prior year.
• Total Debt for Q4 2025 stood at $8.9 million, down from $10.1 million in the prior quarter.
• The five-year high for Total Debt was $29.4 million in Q2 2024, with the low at $1.0 million in Q2 2022.
• The 5-year median for Total Debt is $9.9 million (2023), against an average of $10.2 million.
• The sharpest annual moves came in 2022 and 2023: Total Debt slumped 76.77% in 2022, then jumped 1042.45% in 2023.
• BioLineRx's Total Debt stood at $2.8 million in 2021, then jumped by 268.81% to $10.2 million in 2022, then slipped by 3.88% to $9.8 million in 2023, then jumped by 37.49% to $13.4 million in 2024, then sank by 33.47% to $8.9 million in 2025.
• Business Quant data shows BLRX's Total Debt at $8.9 million in Q4 2025, $10.1 million in Q3 2025, and $11.2 million in Q2 2025.